Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we aimed to assess the predictive and prognostic value of pr...

Full description

Bibliographic Details
Main Authors: Thomas Bartl, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer, Christoph Grimm
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Biomolecules
Subjects:
immunotherapy
immune checkpoint inhibitor
biomarker
overweight
RECIST
Online Access:https://www.mdpi.com/2218-273X/11/11/1700

Internet

https://www.mdpi.com/2218-273X/11/11/1700

Similar Items